Neuroendocrine Hormone Status and Diuretic Response to Atrial Natriuretic Peptide in Patients with Acute Heart Failure
Open Access
- 31 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 9 (6) , 4077-4087
Abstract
Aims: Given the various effects of sacubitril/valsartan in heart failure, a deeper understanding of atrial natriuretic peptide (ANP) actions is warranted. Natriuresis is a fundamental action of ANP in acute heart failure (AHF), whereas the diuretic effect of ANP is different in each patient according to the diversity of renal response to ANP, which is affected by baseline plasma ANP status and deficiency of circulating ANP. Meanwhile, associations between other neuroendocrine hormones and the diuretic response to ANP are unclear. This study investigated the impact of pivotal neuroendocrine hormones on the diuretic effects of exogenous ANP, carperitide. Methods and results: Plasma ANP, renin, aldosterone, and vasopressin levels and the diuretic effect of 0.0125 μg/kg/min of carperitide alone for the first 6 h were prospectively evaluated in 75 patients with AHF. Lower ANP levels were significantly associated with a greater diuretic response to exogenous ANP (r = −0.35, P = 0.002). Additionally, higher vasopressin levels were significantly related to the poor diuretic effects of exogenous ANP (r = −0.54, P < 0.001). Plasma ANP and vasopressin concentrations were not significantly correlated (r = 0.19, P = 0.10). Baseline systolic blood pressure, renal function, and prior use of loop diuretics did not predict the diuretic response to exogenous ANP, whereas vasopressin levels independently predicted a diuretic response to exogenous ANP (P < 0.001), as well as lower plasma ANP levels (P = 0.027). Conclusions: Vasopressin status was significantly associated with the diuretic response to exogenous ANP in AHF, independent of plasma ANP status. The results may provide a better understanding of the actions of sacubitril/valsartan.Keywords
Funding Information
- Daiichi-Sankyo
- Daiichi-Sankyo
This publication has 30 references indexed in Scilit:
- Targeting the renin–angiotensin–aldosterone system in heart failureNature Reviews Cardiology, 2013
- Association of Arginine Vasopressin Levels With Outcomes and the Effect of V2 Blockade in Patients Hospitalized for Heart Failure With Reduced Ejection FractionCirculation: Heart Failure, 2013
- Renal hyporesponsiveness to atrial natriuretic peptide in congestive heart failure results from reduced atrial natriuretic peptide receptor concentrationsAmerican Journal of Physiology-Renal Physiology, 2007
- Heart FailureJACC, 2007
- Vasopressin Antagonism in Heart FailureJACC, 2005
- Vasopressin: a new target for the treatment of heart failureAmerican Heart Journal, 2003
- Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD).Circulation, 1990
- Arginine vasopressin and the renal response to water loading in congestive heart failureThe American Journal of Cardiology, 1986
- Increased plasma arginine vasopressin levels in patients with congestive heart failureJACC, 1983
- Radioimmunoassay of Plasma Arginine Vasopressin in Hyponatremic Patients with Congestive Heart FailureNew England Journal of Medicine, 1981